A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Trial Profile

A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs LC28 0126 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 12 Dec 2016 Interim results assessing tolerability and pharmacokinetics published in the British Journal of Clinical Pharmacology (2016).
    • 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 13 Mar 2014 Status changed from recruiting to completed as rported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top